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ABSTRACT
Introduction. Psoriasis is a debilitating, chronic inﬂammatory systemic disease affecting around 2% of the South
American population. Biological therapies offer the possibility of long-term therapy with improved safety and
efﬁcacy.
Methods. We conducted a multicentre, open-label, single-arm, Phase IIIb/IV study of adult patients (18–75 years)
with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. Patients
received efalizumab subcutaneously (1.0 mg/kg/wk). The primary endpoint was the proportion of patients achieving
a Physician Global Assessment (PGA) rating of “excellent” or “cleared” at Week 24. Safety outcomes were adverse
events (AEs), serious AEs (SAEs) and abnormalities on laboratory tests.
Results. Of 189 patients included in the intent-to-treat and safety populations, 104 (55.0%) were of Hispanic or
Latino ethnicity. At Week 24, 92/189 (48.7%) patients achieved or maintained a PGA rating of “excellent” or
“cleared”. AEs were reported by 161/189 (85.2%) patients, SAEs by 21/189 (11.1%). One patient died during the
study (meningoencephalitis). Laboratory ﬁndings were consistent with previous experience.
Conclusions. Efalizumab demonstrated sustained control of psoriasis up to 24 weeks in patients from Latin America,
conﬁrming results seen in Phase III studies conducted in North America and Europe.
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Introduction
P
soriasis is a T-cell-mediated, chronic inﬂam-
matory systemic disorder requiring long-term
treatment. Conventional systemic therapies are
associated with serious toxicities that can limit
long-term use [1]. Efalizumab is a recombinant,
humanized, monoclonal immunoglobulin G1 anti-
body that exerts antipsoriasis effects by blocking
T-cell-dependent functions mediated by leucocyte
function-associated antigen-1 [2]. Its efﬁcacy
and safety have been investigated in a clinical
71
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North America that included over 2800 patients
with moderate-to-severe psoriasis [3–10]. The
open-label, Phase IIIb/IV study discussed here was
performed to collect conﬁrmatory data on the efﬁ-
cacy and safety of efalizumab in a previously unre-
ported Latin American population.
Methods
This was a 24-week, open-label, single-arm
Phase IIIb/IV study (protocol IMP25161;
ClinicalTrials.gov registration NCT00287118)
conducted in 23 centres in Argentina, Brazil and
Mexico between October 2004 and May 2006.
Patients aged 18–75 years with moderate-to-
severe plaque psoriasis who were candidates for
systemic therapy or phototherapy were eligible.
The extent of psoriasis had to involve at least 10%
of total body surface area. Discontinuation of any
systemic psoriasis treatment was required prior to
commencement of the trial; in the case of biolo-
gics, a 3-month washout period was required. For
women of childbearing potential and for men
whose partners could become pregnant, consent to
use an acceptable method of contraception and
agreement to continue to practise an acceptable
method of contraception for the duration of their
participation in the trial and up to 3 months
after the last dose of efalizumab, were mandatory
for study participation. In addition, treatment
regimens of b-blockers, angiotensin-converting
enzyme inhibitors, antimalarial drugs, quinidine,
interferon, or lithium had to be stable for at least
28 days prior to the ﬁrst dose of trial medication.
Key exclusion criteria included guttate, erythro-
dermic or pustular psoriasis as the sole or pre-
dominant form of psoriasis. Patients were also
ineligible if they had active disease rebound during
or following discontinuation of previous efali-
zumab treatment (i.e. a Psoriasis Area and Severity
Index [PASI] > 125% from baseline and/or new
predominant morphology of psoriasis) if this
outcome was related to efalizumab adverse events
(AEs) or to lack of efalizumab efﬁcacy; however,
patients were eligible for study drug medication if
active disease rebound was due to a nondrug
reason (e.g. infection or vaccination). Other exclu-
sion criteria were as follows: history of severe
allergic or anaphylactic reactions to humanised
monoclonal antibodies; history of or ongoing
uncontrolled infection; seropositivity for HIV,
hepatitis B or C virus; pregnancy or lactation;
white blood cell count <4 ¥ 10
9/L or >14 ¥ 10
9/L;
history of clinically signiﬁcant thrombocytopenia,
bleeding disorders or a platelet count <100 ¥ 10
9
cells/L; history of active tuberculosis; presence of
malignancy within the past 5 years (except fully
resolved basal cell or squamous cell skin cancer);
hepatic cirrhosis; serum creatinine >2 times the
upper limit of normal; hospital admission for
cardiacdisease,stroke,orpulmonarydiseasewithin
the last year; history of substance abuse within the
last 5 years; and any medical condition that, in the
judgementoftheinvestigator,wouldjeopardizethe
subject’s safety following exposure to study drug.
The study complied with the Declaration of Hels-
inki and Good Clinical Practice guidelines, with
approval by the independent ethics committee/
institutional review board for each country.
Patients gave written informed consent.
Participants underwent initial screening 14 days
before the ﬁrst efalizumab injection. Discontinua-
tion of any systemic psoriasis treatment was
mandatory before starting study medication; no
washout was required. All participants received
efalizumab administered subcutaneously, starting
with an initial conditioning dose of 0.7 mg/kg at
baseline (study Day 0), followed by 23 weekly
doses of 1.0 mg/kg.
Participants were evaluated on study Day 0 and
at Weeks 2, 4, 8, 12 and 24 (or at early treatment
termination), with a follow-up visit at Week 32.
Clinical efﬁcacy assessments performed at all visits
included the dynamic Physician Global Assess-
ment (PGA) and the PASI. Quality of life (QoL)
was assessed at all visits using the Medical Out-
comes Study Short-Form (36-Item) Health Survey
(SF-36) and the Dermatology Life Quality Index
(DLQI).
The PGA measured the global response of all
psoriatic lesions to therapy by comparing the sub-
ject’s present condition to baseline photographs or
body diagrams. The assessor classiﬁed response by
considering erythema, scaling, plaque thickness
and percentage of body surface area affected.
Ratings of cleared and excellent represented a
100% improvement (remission) and 75% to 99%
improvement of all clinical signs and symptoms
relative to baseline, respectively. The PASI deter-
mines the extent of cutaneous psoriasis by dividing
the body into 4 anatomical regions (i.e. head,
trunk, upper limbs, and lower limbs) and, for each
region, grading the severity of erythema,
induration/thickness and scaling from 0 for “none”
to 4 for “very severe”. The percentage of the
region affected by disease (graded from 0 for
“none” to 6 for 90% to 100% involvement, is also
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evaluates the severity of symptoms in terms of the
total body surface area affected: this score can
range from 0 to 72, with higher scores indicating
more severe disease. The DLQI consists of 10
questions concerning the impact of skin disease
and its treatment on a subject’s life over the past
week. These questions relate to physical discom-
fort, emotional distress, work and leisure activities,
family and social relationships, sexuality and treat-
ment burden. Each question is posed such that
possible responses are “very much”, “a lot”, “a
little” or “not at all”; patients can also indicate that
particular questions are not relevant. DLQI scores
range from 0 to 30, with higher scores indicating
greater impact of disease (i.e. poorer QoL).
Safety assessments, which included treatment-
emergent AEs, serious AEs (SAEs) and AEs
leading to permanent treatment discontinuation,
were coded for analysis using MedDRA. Sum-
maries of AEs were prepared by MedDRA System
Organ Class and Preferred Term for all events,
the most frequent events, all events by severity,
all events by relation to trial medication, all SAEs
and all AEs leading to withdrawal from treat-
ment. The severity of adverse events was assessed
as mild (the patient was aware of the event or
symptom but it was easily tolerated), moderate
(the patient experienced sufﬁcient discomfort to
interfere with, or reduce, his or her usual level of
activity), severe (the patient experienced a signiﬁ-
cant impairment of functioning and was unable
to carry out his or her usual activities) or very
severe (the patient’s life was at risk from the
event). A serious adverse event was deﬁned as an
event resulting in death or that was life-
threatening, required hospitalization or prolonga-
tion of existing hospitalization, resulted in
persistent or signiﬁcant disability or incapacity,
was a congenital anomaly or birth defect, or was
a medically important condition (the event did
not have to be immediately life-threatening or
result in death or hospitalization, but was clearly
of major clinical signiﬁcance). Routine clinical
laboratory evaluations comprised haematology
(i.e. red blood cell count, haemoglobin, haemato-
crit, platelet count, white blood cell count and
white blood cell differential) and biochemistry
tests (i.e. urea and electrolytes, liver function,
blood urea nitrogen, blood glucose, creatine
phosphokinase, and uric acid) performed at base-
line and at Weeks 2, 12 and 24 (or at early treat-
ment termination). Platelet counts were also
performed at Weeks 4 and 8.
Analysis Populations
The following populations were deﬁned for
analysis:
(a) Intent-to-treat (ITT) and safety population:
patients who received 1 dose of trial
medication.
(b) Per-protocol (PP): all patients who did not
have major protocol violations. The PP popu-
lation was used for supportive analyses of the
primary and secondary endpoints.
Outcome Measures
The primary efﬁcacy endpoint was the proportion
of patients with a PGA score of “excellent” or
“cleared” at Week 24 (ITT and PP populations).
The secondary endpoint was the proportion of
patients achieving “at least good disease control”
at Week 24, deﬁned as a PASI score of <8o ra
50% reduction from baseline in PASI score
(PASI-50), a DLQI score of <6, and no SAEs,
treatment-related SAEs, or early withdrawal (ITT
and PP populations). This endpoint provides a
comprehensive assessment of beneﬁt–risk ratio
and takes into account the multidimensional
aspects of psoriasis. It is similar to the “safe psor-
iasis control” measure proposed in recent publi-
cations [11,12]. The disease control endpoint was
also evaluated in a sensitivity analysis, which
excluded the PASI-50 measure from the compos-
ite endpoint (i.e. the only PASI requirement was a
score of <8).
Tertiary endpoints were the proportion of
patients achieving a 75% reduction from base-
line in PASI score (PASI-75) and PASI-50; changes
in DLQI and SF-36 scores; and changes in scores
for the PASI, Nail Psoriasis Severity Index, Pal-
moplantar Pustular Psoriasis Area and Severity
Index, and Psoriasis Scalp Severity Index (ITT
population). Results of the nail, scalp and pal-
moplantar psoriasis assessments are reported
elsewhere [13].
Analyses of efﬁcacy in the ITT population were
performed using the last observation carried
forward (LOCF) approach. The primary endpoint
was also analysed using the nonresponder imputa-
tion technique, in which all patients with missing
data at Week 24 were counted as nonresponders.
No formal hypothesis testing or adjustments were
performed. It was estimated that 220 patients
would have to be screened to yield a sample of
sufﬁcient size to accurately assess efalizumab’s
safety and efﬁcacy proﬁle in this target population.
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Between October 2004 and September 2005, 220
patients were screened, of whom 31 patients were
considered screening failures, mostly for reasons
related to laboratory results. Thus, 189 were
enrolled and received treatment (ITT and safety
populations). A total of 137 patients (72.5%) com-
pleted the 24-week treatment period. The main
reasons for discontinuation from the treatment
period were AEs in 30 patients (57.7%), lack of
efﬁcacy in 11 patients (21.2%), and protocol vio-
lation by 2 patients (3.8%). The PP population
comprised 124 patients.
The median age of patients in the ITT popula-
tion was 46 years (range 19–74 years), two-thirds
were men, and 55% were of Hispanic or Latino
ethnicity (Table 1). The mean  standard devia-
tion (SD) PASI score at baseline was 24  9.5 and
59.0% had a baseline PASI score of 20 points.
Reported medications at baseline were typical of a
psoriasis population, with nonsteroidal anti-
inﬂammatory drugs, analgesics and topical psoria-
sis medications frequently used. The mean (SD)
time on treatment was 139  45 days. Almost two-
thirds of patients (64.5% [122/189]) received all 24
planned weekly injections.
Endpoints
In the ITT population, 48.7% (92/189) of patients
achieved or maintained a PGA score of “excellent”
or “cleared” (95% conﬁdence interval [CI] 41.6–
55.8%; Fig. 1a) at Week 24 (nonresponder
imputation analysis 46.0% [87/189]; 95% CI 38.9–
53.1%); in the PP population this rate was 65.3%
(81/124; 95% CI 56.9–73.7%). At Week 24, 67.7%
(128/189)intheITTpopulationachievedormain-
tained a PGA score of “good” or better (Fig. 1a).
In the ITT population, 47.1% (89/189)
achieved “at least good disease control” at Week
24 (95% CI 40.0–54.2%); in the PP population
this rate was 65.3% (81/124; 95% CI 56.9–
73.7%). “Safe disease control” at Week 24 was
achieved by 50.0% (62/124; 95% CI 41.2–58.8%)
in the PP population and 36.0% (68/189; 95% CI
29.1–42.8%) in the sensitivity analysis.
At Week 24, 90 patients (47.6%; 95% CI 40.5–
54.7%) were classiﬁed as PASI-75 responders and
132 (69.8%; 95% CI 63.3–76.4%) were classiﬁed
as PASI-50 responders (Fig. 1b).
Median PASI and DLQI scores with respect to
study visit are summarized in Table 2. Percentage
change from baseline in PASI score improved by
visit (Fig. 1c). At Week 12, the median percentage
change from baseline was 61.9% (interquartile
range 34–79%) and the mean  SD was
49.0%  44.0%; at Week 24, using LOCF, the
median percentage change from baseline had
increased to 72.8% (95% CI 65.3–78.6%) and the
mean  SD had increased to 55.2%  48.5%. At
Week 24, the median improvement in DLQI score
(N = 180) was 6 (95% CI 5–7). The median
improvements in SF-36 total (N = 177), physical
(N = 179) and mental (N = 180) scores were 35.5
(95% CI 21.4–57.3), 17.2 (95% CI 9.7–23.6) and
22.5 (95% CI 11.3–32.0), respectively.
Safety andTolerability
During the treatment phase, 161/189 (85.2%)
patients reported at least one AE; 152 (80.4%)
experienced at least one AE during Weeks 0–12 vs
Table 1 Baseline demographic and disease
characteristics of the intent-to-treat population (N = 189)
Characteristic Value
Median age (range), years 46 (19–74)
Male, n (%) 134 (70.9)
Race, n (%)
White 125 (66.1)
Black 7 (3.7)
Asian 0
Other 57 (30.2)
Hispanic or Latino ethnicity, n (%) 104 (55.0)
Median weight (range), kg 80 (46–120)
Median body mass index (range), kg/m
2* 28.7 (16.5–45.3)
Median duration of psoriasis (range), years* 15 (1–46)
Patients with prior psoriasis therapy, n (%) 158 (83.6)
Patients with prior systemic therapy, n (%)* 153 (81.0)
Median PASI score (range)
† 22 (7–61)
PASI score 20, n (%)
‡ 111 (59.0)
Median DLQI score (range)
§ 11.5 (0–29)
Median SF-36 score (range)
Total score
¶ 550.3 (66.4–778.5)
Mental component score
§ 262.5 (28.0–396.0)
Physical component score** 294.4 (21.7–395.0)
*Psoralen ultraviolet A therapy, ciclosporin, systemic corticosteroids, metho-
trexate, systemic retinoids, mycophenolate mofetil, thioguanine, hydroxyurea,
sirolimus, azathioprine and 6-mercaptopurine; †N = 180; ‡N = 188; §N = 180;
¶N = 177; **N = 179.
DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity
Index; SF-36, Medical Outcomes Study Short-Form (36-Item) Health Survey.
Table 2 Median Psoriasis Area and Severity Index
(PASI) and Dermatology Life Quality Index (DLQI) scores
over the duration of the 24-week treatment period in the
intention-to-treat population using last observation carried
forward analysis
Visit
Median PASI score
(interquartile range)
Median DLQI score
(interquartile range)
Baseline 21.9 (16–29) 11.5 (7–16)
Week 2 17.2 (13–26) 8.0 (4–12)
Week 4 14.5 (11–20) 7.0 (3–11)
Week 8 10.4 (7–16) 5.0 (1–9)
Week 12 7.9 (5–15) 4.0 (1–9)
Week 24 5.8 (2–14) 3.0 (1–9)
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(66.1%), at least one AE was considered possibly
or probably related to efalizumab.
The most frequently reported treatment-
emergent AEs, particularly during the ﬁrst
12 weeks, were consistent with the syndrome of
“acute AEs” (inﬂuenza-like symptoms such as
headache, fever, chills, myalgia, nausea or vomit-
ing within 48 hours of administration) (Table 3).
Post-treatment AEs were reported in 69 patients
(36.5%), 20 of whom continued with efalizumab
after completing the study treatment period.
Thirty-one patients (16.4%) experienced a total of
46 treatment-emergent AEs that led to withdrawal
of efalizumab; psoriasis (6.3%) and arthritis (2.1%)
were the most common AEs cited.
SAEs were reported in 21 patients (11.1%)
and included psoriasis, arthritis, arthralgia and
Figure 1 (a) Physician Global
Assessment score over time during
treatment with efalizumab (intent-to-
treat population, last observation
carried forward; N = 189). (b) Propor-
tion of responders (95% CI) achieving
a 75% reduction from baseline in
Psoriasis Area and Severity Index
(PASI) score (PASI-75) and a 50%
reduction from baseline in PASI score
(PASI-50) over time during treatment
with efalizumab (intent-to-treat popu-
lation, last observation carried
forward). (c) Mean and median
(95% CI) percentage improvement
in PASI score over time during treat-
ment with efalizumab (intent-to-treat
population, last observation carried
forward).
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patients (11.6%). Treatment-emergent musculo-
skeletal and connective tissue disorders (most
commonly arthralgia, myalgia, back pain, and
arthritis) were reported in 71 patients (37.6%).
One patient died during the study from meningo-
encephalitis probably of bacterial origin. Due to
the mechanism of action of efalizumab, it could
not be excluded that efalizumab played a role in
the evolution of the infection. Five infection-
related SAEs occurred in four patients during the
treatment period of the study (cytomegalovirus
infection, meningitis aseptic, pneumonia, tooth
abscess and sepsis [the tooth abscess and sepsis
were reported in the subject who died]). The
pneumonia, tooth abscess and sepsis were con-
sidered to be probably related to the trial medi-
cation and the cytomegalovirus infection and
Table 3 Summary of the most frequent treatment-
emergent adverse events (TEAEs) (reported in 5% of
patients) in the safety population (N = 189)
Adverse events
Number of patients (%)
Weeks 1–12 Weeks 13–24
Total 152 (80.4) 67 (35.4)
Serious TEAEs 15 (7.9) 8 (4.2)
Severe or very severe TEAEs 29 (15.3) 16 (8.5)
Discontinued because of a TEAE 21 (11.1) 11 (5.8)
TEAE term
Headache 68 (36.0) 6 (3.2)
Arthralgia 23 (12.2) 6 (3.2)
Myalgia 21 (11.1) 7 (3.7)
Inﬂuenza-like illness 20 (10.6) 3 (1.6)
Pyrexia 20 (10.6) 3 (1.6)
Chills 18 (9.5) 0
Back pain 13 (6.9) 5 (2.6)
Diarrhoea 13 (6.9) 1 (0.5)
Nausea 13 (6.9) 1 (0.5)
Inﬂuenza 12 (6.3) 2 (1.1)
Psoriasis 10 (5.3) 8 (4.2)
Table 4 Median (range) clinical laboratory values in the safety population
Parameter (unit)
Visit
Baseline Week 12 Week 24
No. pts Value No. pts Value No. pts Value
Red blood cell count (¥10
12/L) 186 5.0 180 5.0 155 5.0
(3.8–6.9) (3.4–6.9) (3.6–6.1)
Haemoglobin (g/L) 186 151 180 150 155 150
(114–202) (103–190) (99–189)
Haematocrit 186 0.45 180 0.45 155 0.44
(0.36–0.61) (0.32–0.62) (0.35–0.55)
White blood cell count (¥10
9/L) 186 7.0 180 10.0 154 10.2
(3.8–14.5) (5.8–24.7) (4.5–17.6)
Lymphocytes (¥10
9/L) 186 1.8 180 4.2 154 4.0
(0.7–3.7) (1.4–10.3) (0.7–9.7)
Neutrophils (¥10
9/L) 186 4.4 180 5.0 154 4.9
(1.6–12.4) (1.6–20.5) (1.5–12.7)
Platelets (¥10
9/L) 186 249 169 240 155 241
(127–556) (82–3125) (105–590)
Sodium (mmol/L) 186 140 181 140 152 141
(133–148) (134–147) (131–148)
Potassium (mmol/L) 185 4.3 181 4.3 152 4.4
(3.5–5.1) (3.7–5.6) (3.5–13.6)
Blood urea nitrogen (mg/dL) 176 13.7 139 14.0 104 13.6
(4.7–32.0) (5.3–24.3) (5.0–23.9)
Creatinine (mmol/L) 186 78 180 77 151 79
(34–143) (33–161) (41–138)
Total bilirubin (mmol/L) 186 9.6 180 8.3 151 8.4
(2.9–32.1) (2.6–35.2) (3.2–37.6)
Blood glucose (mmol/L) 186 5.1 180 5.2 152 5.2
(3.4–17.7) (3.0–15.5) (3.6–23.8)
Alanine aminotransferase (U/L) 185 29.0 181 26.0 152 26.5
(6.0–102.0) (7.0–241.0) (8.0–122.0)
Aspartate aminotransferase (U/L) 185 23.0 181 23.0 151 23.0
(11.0–69.0) (10.0–109.0) (10.0–123.0)
Alkaline phosphatase (U/L) 186 80.5 181 85.0 151 86.0
(39.0–189.0) (32.0–244.0) (39.0–298.0)
Lactate dehydrogenase (U/L) 185 187.0 181 172.0 152 167.5
(76.0–398.0) (152.0–200.0) (86.0–353.0)
Creatine phosphokinase (U/L) 186 100.5 181 92.0 152 87.5
(17.0–1369.0) (16.0–470.0) (19.0–1528.0)
Uric acid (¥10
9/L) 186 364.0 181 375.0 152 356.0
(149.0–690.0) (156.0–714.0) (153.0–684.0)
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the post-treatment period, pneumonia was
reported in the patient who died, which was also
considered to be probably related to the trial
medication.
Total white blood cell, lymphocyte and neutro-
phil counts increased during treatment (Table 4).
For most patients the maximum toxicity was grade
1. At baseline, none of the 53 patients with
evaluable blood samples tested positive for binding
antibodies to efalizumab. At Week 32, 9/96 (9.4%)
patients tested positive for binding antibodies to
efalizumab.
Discussion
In this study, 48.7% of patients reached a PGA
rating of at least “excellent” at 24 weeks (ITT
LOCF analysis) and 47.6% were classiﬁed as
PASI-75 responders at this timepoint, consistent
with rates reported in European and North Ameri-
can populations [5,6,10]. These ﬁndings, however,
should be interpreted while considering the main
study limitations, which were the open-label
design and the lack of placebo arm.
We used an additional measure of “at least good
disease control” to determine outcome. As for the
“safe psoriasis control” measure proposed by Papp
and Henninger [11,12], this endpoint reﬂects
improvements not only in the clinical severity of
lesions but also in QoL and an assessment of the
tolerability of treatment. By this measure, nearly
half of the patients studied derived important
beneﬁt from efalizumab treatment without incur-
ring major safety concerns.
The safety proﬁle for efalizumab was also
acceptable and consistent with previous results
[3–10]; no new safety concerns were identiﬁed.
AEs occurred most frequently during the ﬁrst 12
weeks of treatment, the most common events
being consistent with the syndrome of inﬂuenza-
like symptoms or acute AEs that are known to
occur with initial efalizumab treatment. Similar to
previous trials, the SAEs and AEs most commonly
leading to treatment discontinuation were related
to exacerbation of psoriasis and/or arthritis [3–10].
Laboratory ﬁndings were also consistent with pre-
vious experience. Treatment-emergent musculo-
skeletal and connective tissue disorders were seen
in 37.6% of patients, and long-term data have
indicated that the incidence of these AEs remains
stable for up to 3 years of continuous efalizumab
treatment [13].
Although results from the present study indi-
cate that efalizumab has an acceptable safety
proﬁle in patients with psoriasis, opportunistic
infections have been reported in post-marketing
surveillance. In particular, instances of progres-
sive multifocal leucoencephalopathy due to JC
virus infection have been observed in patients
receiving efalizumab continuously for more than
3 years. After evaluation of all available safety
data, the European Medicines Agency has con-
cluded that the beneﬁts of efalizumab therapy no
longer outweigh the associated risks and have
recommended suspension of marketing authori-
zation (as of 19 February 2009). In addition,
efalizumab has been voluntarily withdrawn from
the US market.
To our knowledge, the present study is the only
prospective trial conﬁrming the efﬁcacy and safety
of efalizumab in a Latin American population with
moderate-to-severe psoriasis.
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